Participant profile: 4P-Pharma
Translating science to product
4P-Pharma has a mission to reduce attrition rates and developmental costs, enrich the drug candidate pipeline and translate science into human health products. To this end the company can partner with academic institutions or biotechnology companies.
Enter your email address to follow The Hive and get the latest updates on participants and milestones – followed by the email address submission box.
Using development expertise to get more innovative drugs through the pipeline
4P-Pharma was founded in response to the urgent need to increase the number of innovative therapeutics entering the drug development pipeline for cancer and inflammatory diseases. The 4P team has an important role in this process, combining complementary expertise and seasoned experience in pharmacology, biology, drug development, formulation and translational research.Read more
The founders of 4P-Pharma have decades of experience in maturating early-stage technologies from drug discovery level up to clinical phase IIa in several fields, from medical devices to pharmaceutical and biological compounds, from new chemical entities to generic drug repositioning.
4P-Pharma has a special focus on cancer and inflammatory diseases and extensive know-how in pre-formulation/formulation, critical steps in early drug discovery and drug screening, regulatory knowledge, manufacturing processes and more. The company is maturing a diversified pipeline of technologies in-house, both proprietary and co-developed with external partners.
Answering high unmet needs is the prime focus of 4P-Pharma. To date the company develops six technologies in its laboratory with a special focus on oncology. Their pipeline includes New Chemical Entities, biologics, and fixed dose combinations for the treatment of several type of cancer and cancer resistance to chemotherapies.
Meet the team
Revital Rattenbach, PhD
Chief Executive Officer and Co-Founder
In 2014, Dr. Rattenbach co-created 4P-Pharma in response to the urgent need to increase the number of innovative therapeutics entering the developing drug pipeline for cancer and inflammatory diseases. She is the company CEO and holds a PhD in Aging Biology from Paris-Descartes University, a MBA from IAE Paris and has attended HEC Challenge+ School of Management.
Itschak Lamensdorf, PhD
Chief Scientific Officer and Co-Founder
Dr. Lamensdorf leads the company’s drug pipeline development in oncology, inflammation and abuse-deterrent fields. He also founded and is President of Pharmaseed, an Israeli CRO, and has been responsible for its scientific course of expansion, national and international collaborations, and staff excellence. Dr. Lamensdorf was also CEO of Thrombotech, a company developing new technology for treatment of stroke.
Luigi Formicola, PhD
BD & Project Manager
Luigi Formicola joined 4P-Pharma in 2014 to manage and administrate internal projects and business development activities. He holds a PhD in Morphogenetic and Cytological Sciences from La Sapienza University, Rome, Italy.
Céline Martin, PhD
R&D Lab Manager
Céline Martin joined the company in 2014 as a Preclinical Study Director and R&D Lab Manager, and she oversees the company’s research team studies and activities. She holds a PhD in Biology from Burgundy University, Dijon, France.
"The Hive program and Elsevier’s R&D solutions will help us speed up our research processes and enable us to move our drug pipeline as quickly as possible from the preclinical to the clinical stage for the patients benefit." Dr. Revital Rattenbach
"The challenge for a biotech company is to be very innovative, move fast and in the right direction. This program will give the team access to a complementary, broad range set of software that will be useful for research design, analysis, and stay up-to-date with the latest trending ideas in the field." Dr. Itschak Lamensdorf
"As a preclinical scientist, staying up-to-date with the latest methods and models is paramount for the design and conduct of my studies. I have no doubt that ScienceDirect and Embase will be valuable additions for my work." Dr. Céline Martin
"Data mining can become very time-consuming without access to centralized databases. I anticipate that our projects will benefit from tools such as PharmaPendium, Embase and Pathway Studio. These softwares will allow us to quickly access invaluable information regarding drug candidate mode of actions and properties, which in turn will help us in our projects prioritization." Dr. Luigi Formicola
Learn more about Elsevier's R&D solutions for drug discovery
and development utilized by 4P-Pharma:
Improve R&D productivity with a chemistry research solution that delivers experimental facts on chemical structures, properties, reactions and procedures.
Learn more about Reaxys
Reaxys Medicinal Chemistry
Empower hit identification and lead optimization with normalized compound–target affinity data and comprehensive pharmacokinetic, efficacy, toxicity, safety and metabolic profiles.
Learn more about Reaxys Medicinal Chemistry
Increase the discovery of biomedical evidence to support critical life sciences functions, with access to the world's most comprehensive biomedical literature database.
Learn more about Embase
Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.
Learn more PharmaPendium
Enable researchers to more effectively and efficiently search authoritative, full-text scientific, technical and health content through the use of smart, intuitive functionality.
Learn more about ScienceDirect
Enable better understanding of biological processes underlying disease progression and treatment response, with a solution that helps researchers interpret experimental data from scientific literature.
Learn more about Pathway Studio
Help researchers discover trends, partners and experts with the world’s largest abstract & citation database of peer-reviewed literature, including tools to track, analyze and visualize research.
Learn more about Scopus